Acton medical device firm to launch clinical trial studying sepsis system
PHOTO | Courtesy of Google Maps
Bluejay Diagnostics' Acton office
Bluejay Diagnostics in Acton is launching a clinical trial to study the efficacy of its Symphony System in patients with sepsis, a life-threatening complication from infection.
The Symphony System is designed to detect specific biomarkers in patients with sepsis and indicate when additional provider intervention is necessary, according to a Wednesday press release from Bluejay.
The objective of the study is to better understand patient mortality tied to specific biomarkers in patients with sepsis or in septic shock. Patients in the trial will be those in the intensive care unit or likely to be admitted to the ICU.
“Sepsis is a leading cause of hospitalization and mortality, with about 1.7 million people developing sepsis in the U.S. alone,” Bluejay Chief Medical Advisor Dr. Mark Feinberg said in the press release. “Any new tests or tools that can help better guide management of this critical population could be impactful to the medical field.”
The Bluejay tool to be tested in the trial is its Symphony IL-6 test, which tests levels of a certain protein, IL-6, in the cells. The objective of the study is to determine the IL-6 levels associated with mortality rates in sepsis patients.
“We are very excited to start these important studies. In addition to being one step closer to commercialization, these studies will help to identify potential competitive advantages of the Symphony IL-6,” Bluejay CEO Neil Dey said in the press release.
The clinical trial will take place at multiple medical centers.
WBJ Web Partners
Most Recent
Most Recent
0 Comments